Marco Meglio

Long-term data confirms givinostat's safety and efficacy in delaying Duchenne muscular dystrophy progression, offering hope for patients and families.

The director of the Norman Fixel Institute for Neurological Diseases at UF Health talked about prevention, understanding disease mechanisms, and creating a patient-centered care model in Parkinson disease. [WATCH TIME: 5 minutes]

A recent Canadian study reported similar trends in polysomnography and positive airway pressure initiation over a decade between patients with Parkinson disease and matched controls.

Amylyx Pharmaceuticals discontinued its AMX0035 program for progressive supranuclear palsy after a phase 2b trial failed to show efficacy.

MediciNova's COMBAT-ALS trial reaches full enrollment, exploring ibudilast's potential to treat ALS and improve patient outcomes.

The neurophysiologist at Allegheny Health Network shared his clinical experience with tofersen in patients with SOD-1 ALS, while emphasizing the critical role of accessible genetic testing for patient identification. [WATCH TIME: 3 minutes]

A pivotal phase 3 study explores ampreloxetine's potential to treat neurogenic orthostatic hypotension in multiple system atrophy patients, aiming for FDA approval.

Merz initiates phase 3 trials for Xeomin, targeting migraine prevention in adults, aiming to fill gaps in current treatment options.

Tracey Dawson, PhD, senior vice president of U.S. Therapeutic Area Head of Neuroscience at Novartis, expanded on the recently launched SMAshing My Limits campaign, a community-driven project aimed to address needs of developing teens with SMA.

The vice chair of education for the department of neurology at Mass General outlined her AUPN 2025 session on supporting clinician educators through recognition, career development, and institutional frameworks for advancement. [WATCH TIME: 4 minutes]

The head of the neurology department at Vall d’Hebron University Hospital provided clinical thoughts on fremanezumab’s expanded approval in pediatric migraine, the phase 3 SPACE study, and where future treatment may hold.

Serum NPTX2 emerges as a novel biomarker in ALS, with combined NPTX2 and NfL levels improving survival prediction and disease monitoring.

Regeneron's cemdisiran shows promising results in treating generalized myasthenia gravis, paving the way for a potential new drug application in 2026.

The neurologist at Maimonides Medical Center and SUNY Downstate shared how interactive simulations give neurology trainees the chance to practice skills, gain feedback, and move beyond passive learning. [WATCH TIME: 3 minutes]

The FDA has accepted the IND for COYA 302, a Treg-targeting combination therapy for ALS, clearing the way for a pivotal phase 2 multicenter trial.

Efgartigimod shows promise in treating seronegative myasthenia gravis, offering hope for patients with limited options and paving the way for new therapies.

New research reveals that socioeconomic factors, rather than cardiovascular risks, significantly influence the occurrence of nonfocal transient neurologic attacks in older adults.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the use of GLP-1 RAs in neurology.

A newly reported case highlights acute retinal necrosis from varicella zoster virus in a patient with multiple sclerosis on dimethyl fumarate, underscoring the need to consider non–optic neuritis causes of vision loss.

Lea Grinberg, MD, PhD, a neuropathologist at Mayo Clinic Florida, discussed how tau accumulation and orexin neuron loss drive early sleep disturbances in Alzheimer disease and the potential for sleep-based biomarkers.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Danielle Andrade, MD, MSc. [LISTEN TIME: 13 minutes]

A new study reveals NT-0796's potential to reduce neuroinflammation in Parkinson's disease, paving the way for future treatments.

The decision stemmed from the DREAM study, which found that the Genio system was effective regardless of a patient’s sleeping position, which was particularly important considering patients spend on average 35% to 40% of in a supine position.

At AHS 2025, the associate clinic director at the UC San Diego talked about the cautious use of cannabinoids in migraine and the importance of standard therapies before cannabinoids. [WATCH TIME: 3 minutes]

The director of the Brotman Facial Pain Clinic at the University of Maryland talked about emerging preclinical evidence supporting adenosine A3 receptor activation for post-traumatic trigeminal neuropathic pain. [WATCH TIME: 5 minutes]

A recent study highlights that hearing aids significantly lower dementia risk in younger patients with hearing loss, emphasizing the need for early intervention.

The European Medicines Agency has accepted NewAmsterdam Pharma’s application for obicetrapib, an oral CETP inhibitor that lowers LDL-C and shows promise in reducing Alzheimer-related biomarkers.

At AHS 2025, Elizabeth Seng, PhD, professor of neurology at Albert Einstein College of Medicine, presented findings from a study showing that migraine was associated with increased odds of ischemic stroke in veterans.

The chief scientific officer at Alzheon talked about a symposium on the role of amyloid-beta oligomers in AD and phase 3 clinical data of valiltramiprosate presented at AAIC 2025. [WATCH TIME: 5 minutes]

Phase 3 study demonstrates risdiplam's effectiveness in treating presymptomatic spinal muscular atrophy, showing improved outcomes for infants identified through newborn screening.